• Home
  •  / Faraday Pharmaceuticals

Faraday Pharmaceuticals

  • Total Funding$88 M

OverviewSuggest Edit

Faraday Pharmaceuticals is a company specializing in the use of elemental reducing agents to support the quality of life after acute, critical illness. It develops FDY-5301, a therapeutic candidate that helps to destroy hydrogen peroxide and minimize damage to cardiac and skeletal muscle.
TypePrivate
Founded2014
HQSeattle, WA, USMap
Websitefaradaypharma.com

Recent NewsAll News

Latest Updates

Employees (est.) (Jun 2022)20(-4%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Faraday Pharmaceuticals

Brian Blackman

Brian Blackman

Chief Financial and Business Officer
Terry McGuire

Terry McGuire

Director
Stephen A. Hill

Stephen A. Hill

Chief Executive Officer, Director
Tressa Randall

Tressa Randall

Vice President Regulatory Affairs
Patrick C. Rock

Patrick C. Rock

General Counsel & Corporate Secretary
Shannon Wilson

Shannon Wilson

Vice President Clinical Operations
Show more

Faraday Pharmaceuticals Office Locations

Faraday Pharmaceuticals has an office in Seattle
Seattle, WA, US (HQ)
1616 Eastlake Ave E #560
Show all (1)

Faraday Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

2014

Faraday Pharmaceuticals total Funding

$88 m

Faraday Pharmaceuticals latest funding size

$25 m

Time since last funding

3 years ago

Faraday Pharmaceuticals investors

Polaris Partners, ARCH Venture Partners, OUP (Osage University Partners), Washington Research Foundation
Faraday Pharmaceuticals's latest funding round in September 2019 was reported to be $25 m. In total, Faraday Pharmaceuticals has raised $88 m
Show all financial metrics

Faraday Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

Learn more about our premium products
SecurityScorecard logo

Faraday Pharmaceuticals Online and Social Media Presence

Faraday Pharmaceuticals's Trends

Embed Graph

Faraday Pharmaceuticals News and Updates

April 13, 2021

Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol

LONDON and SEATTLE, April 13, 2021 /PRNewswire/ -- Actimed Therapeutics Ltd., a clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, today announced a license agreement for S-oxprenolol to Faraday Pharmaceuticals,...

Faraday Pharmaceuticals Blogs

March 25, 2021

Faraday Pharmaceuticals® Reaches Special Protocol Agreement with the FDA for its Phase 3 Clinical Trial of FDY-5301 in AMI Reperfusion Injury

SPA Agreement Reached with FDA on Protocol Design and Statistical Approach for Phase 3 FDY-5301 Cardiovascular Outcomes Trial
October 30, 2020

Faraday Pharmaceuticals Involved in Important Publication Exploring Iodine Redistribution During Trauma, Sepsis, and Hibernation

October 2020, Seattle – Faraday Pharmaceuticals contributed to research recently published that analyzed the role of iodine redistribution during trauma, sepsis, and hibernation.

 Faraday Pharmaceuticals Frequently Asked Questions

  • When was Faraday Pharmaceuticals founded?

    Faraday Pharmaceuticals was founded in 2014.

  • Who are Faraday Pharmaceuticals key executives?

    Faraday Pharmaceuticals's key executives are Brian Blackman, Terry McGuire and Stephen A. Hill.

  • How many employees does Faraday Pharmaceuticals have?

    Faraday Pharmaceuticals has 20 employees.

  • Who are Faraday Pharmaceuticals competitors?

    Competitors of Faraday Pharmaceuticals include LimmaTech Biologics, Tiburio Therapeutics and Landos Biopharma.

  • Where is Faraday Pharmaceuticals headquarters?

    Faraday Pharmaceuticals headquarters is located at 1616 Eastlake Ave E #560, Seattle.

  • Where are Faraday Pharmaceuticals offices?

    Faraday Pharmaceuticals has an office in Seattle.

  • How many offices does Faraday Pharmaceuticals have?

    Faraday Pharmaceuticals has 1 office.